Related Experiment Video
Updated: Jul 18, 2026

08:25
Advanced 3D Liver Models for In vitro Genotoxicity Testing Following Long-Term Nanomaterial Exposure
Published on: June 5, 2020
Strategy for genotoxicity testing: hazard identification and risk assessment in relation to in vitro testing
V Thybaud1, M Aardema, J Clements
1Drug Safety Evaluation, Sanofi-aventis, 94400 Vitry sur Seine, France. Veronique.Thybaud@sanofi-aventis.com
Mutation Research
|November 28, 2006
Summary
Expert toxicologists developed guidelines for interpreting in vitro genetic toxicology test results. This strategy aims to reduce unnecessary follow-up testing for agents not posing human health risks.
Area of Science:
- Toxicology
- Genetic Toxicology
- Risk Assessment
Background:
- Regulatory agencies require genetic toxicology testing batteries.
- High rates of positive in vitro findings occur for non-carcinogenic agents.
- Need for standardized interpretation and follow-up testing strategies is recognized.
Purpose of the Study:
- Develop recommendations for interpreting in vitro genetic toxicology test results.
- Propose a strategy for follow-up testing after positive in vitro findings.
- Establish consensus principles for hazard identification and risk assessment.
Main Methods:
- Convened an Expert Working Group with international authorities from industry, government, and academia.
- Utilized a consensus process to develop guiding principles and a decision tree framework.
- Analyzed case studies based on actual test results to inform consensus opinions.
Main Results:
- A framework and decision tree were developed for assessing the need for and selection of follow-up tests.
- Criteria were defined for determining when positive in vitro results indicate low or no concern.
- Factors for follow-up testing include reproducibility, cytotoxicity, and historical control data.
Conclusions:
- Consensus principles for interpreting and following up on in vitro genotoxicity tests were established.
- The strategy aims to improve the relevance of genetic toxicology testing to human health risk assessment.
- Further refinement of specific test recommendations beyond initial batteries was not completed due to time constraints.
Related Concept Videos
Mutagenicity and Carcinogenicity
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
In vitro Mutagenesis
To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
Toxicity Testing in Animals
Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
In-vitro Mutagenesis
To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.

